NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

HIMS

HIMS US Stock
$11.1
Open: $12.26 High: $12.26 Low: $10.44 Close: $10.75
Range: 2021-05-06 - 2021-05-07
Volume: 1,217,609
Market: Closed
Powered by Finage Stock APIDelayed data
HIMS
  • CEO:
  • Employees:
  • Sector:
  • Industry:
HIMS News
Latest news about the HIMS
  • Hims & Hers Health, Inc. Announces Response to Recent SEC Guidance Applicable to Warrants Issued by Special Purpose Acquisition Companies ("SPACs")

    Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, today announced that, as a result of guidance provided by the Staff of the Securities and Exchange Commission (the "SEC") on April 12, 2021 for all SPAC-related companies regarding the accounting and reporting for their warrants, it will restate the 2020 and 2019 consolidated financial statements previously issued by Oaktree Acquisition Corp. ("OAC"), as well as the condensed consolidated financial statements included in previously filed quarterly reports (other than the quarterly report filed on August 29, 2019 for the quarterly period ended June 30, 2019). These financial statements, along with the related press releases, the Report of the Independent Registered Public Accounting Firm on the financial statements as of December 31, 2020 and 2019, for the year ended December 31, 2020 and the period from April 9, 2019 (inception) through December 31, 2019 and the stockholder communications describing the relevant portions of the Company’s financial statements for the periods that need to be restated, should no longer be relied upon.

    View More →
  • Here's What Hims & Hers Health, Inc.'s (NYSE:HIMS) Shareholder Ownership Structure Looks Like

    If you want to know who really controls Hims & Hers Health, Inc. ( NYSE:HIMS ), then you'll have to look at the makeup...

    View More →
  • How Jennifer Lopez & Alex Rodriguez's split is a 'business divorce,' minus the marriage

    Here's how Jennifer Lopez and Alex Rodriguez's split could impact the couple's finances

    View More →
  • Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results

    Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, today reported financial results for the fourth quarter and full year ending December 31, 2020.

    View More →
  • Hims & Hers Appoints Two New Board Members

    Andrea Perez and Ambar Bhattacharyya join Hims & Hers Board of Directors to help the company pioneer a better way for patients to access healthcare.

    View More →
  • Replay: IPO Edge Hosts Fireside Chat with GigCapital2 CEO and Cloudbreak CEO to Discuss Merger

    GigCapital2 President and CEO Dr. Raluca Dinu and Cloudbreak CEO Jamey Edwards IPO Edge hosted a live fireside chat with GigCapital2 (NYSE: GIX) on Friday, March 5 at 12:00 EST to discuss the pending merger with UpHealth Holdings, Inc. and Cloudbreak Health. The live event featured GigCapital2 President and CEO Dr. Raluca Dinu and Cloudbreak […]

    View More →
  • TODAY at 12 EST – IPO Edge to Host Fireside Chat with GigCapital2 CEO and Cloudbreak CEO to Discuss Merger

    GigCapital2 President and CEO Dr. Raluca Dinu and Cloudbreak CEO Jamey Edwards IPO Edge will host a live fireside chat with GigCapital2 (NYSE: GIX) on Friday, March 5 at 12:00 EST to discuss the pending merger with UpHealth Holdings, Inc. and Cloudbreak Health. The live event will feature GigCapital2 President and CEO Dr. Raluca Dinu and […]

    View More →
  • Hims & Hers Health, Inc. to Participate in Upcoming Investor Conference

    Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, will participate in Citi’s 2021 Healthcare Services, Medtech, Tools & HCIT Virtual Conference, including a fireside chat presentation with CEO and Co-Founder, Andrew Dudum, on Thursday, February 25, 2021 at 3:20 p.m. E.T. The audio webcast and related materials will be available online at https://investors.forhims.com/.

    View More →
  • Is Hims & Hers Health a Good Way To Play the Telehealth Megatrend?

    On Jan. 20th, Hims & Hers Health (NYSE:HIMS) announced that it will begin trading on the New York Stock Exchange as HIMS stock. How? Well, the company did this by using a Special Purpose Acquisition Company (SPAC). That is, there was a merger into the shell company Oaktree Acquisition Corp. Source: Lori Butcher / Shutterstock.com During the first week of trading, HIMS stock was choppy. However, shares has since been on a nice rally — going from $15.68 to above $22. Additionally, with the SPAC, HIMS was able to raise $280 million. About $75 million came from a private placement from investors like Oaktree clients and Franklin Resources (NYSE:BEN). And before this, the company had raised $158 million in venture capital.InvestorPlace - Stock Market News, Stock Advice & Trading Tips As a whole, HIMS operates a telehealth platform as well as a digital pharmacy. The company is also working on a 300,000 square foot distribution center. Overall, though, the market value of the firm is currently about $4.26 billion. So, what now for HIMS stock? Is it a good bet for this year? 7 Must-Own Stocks in February Well, let’s dive in and take a closer look. Background on the Company Collectively, HIMS is a fairly new company. Back in late 2017, Andrew Dudum and Jack Abraham started the operation. They did this through their own venture capital firm, Atomic. In the first week, HIMS generated $1 million in sales — and would finish the year at $27 million. No doubt, the company nailed the proverbial product-market fit. At first, the focus was on providing telehealth services, such as for erectile dysfunction and hair loss. But HIMS would quickly expand its platform. And in 2018, there was the launch of Hers. That said, there was also moves into categories like mental health, dermatology and primary care. To help with the management of the growing organization, HIMS created its own EHR (Electronic Health Record) system. Moreover, the company’s service is primarily focused on Millennials and the Generation Z cohorts, who do not have insurance. The business model involves a subscription that is about $20 to $30 per month. Yet, the main revenues come from the sales of prescriptions. Now, HIMS is not completely virtual. The company has partnered with a variety of health care operators — such as Ochsner Health, Mount Sinai Health System, and Privia Health — to provide access to in-person visits with doctors. And yes, the market opportunity is truly massive. The spending on prescription drugs comes to about $600 billion a year — and as for primary care, its about $280 billion (according to Deloitte and Grand View Research). However, there are some nagging issues with HIMS stock. First of all, by relying on the sale of drugs, this could mean more pressure to make prescriptions, even if they are not needed. Next, there are the competitive pressures. There are a variety of startups gunning for the telehealth opportunity. But mega tech companies like Amazon (NASDAQ:AMZN) and traditional players like CVS (NYSE:CVS) could be major factors as well. And finally, the valuation on HIMS stock is on the high side. Consider that the price-sales (P/S) ratio is about 30 times. Bottom Line on HIMS stock The growth story at HIMS has been standout. For 2020, the sales are expected to have increased by 66% to $138 million. And as for this year, the forecast is for $179 million and $233 million for 2022. The company is also realizing economies of scale. For example, the gross margins have climbed to 71%. Of course, with the novel coronavirus pandemic, the telehealth market has quickly gone mainstream. Healthcare providers are comfortable with the approach and insurance providers see this as an efficient option. As a result, the public companies in the sector have posted robust gains, such as Teladoc Health (NYSE:TDOC) and American Well (NYSE:AMWL). And as for HIMS stock, it offers investors an interesting twist on the opportunity because of the focus on younger generations, which are likely to be more inclined to use digital services. Thus, when it comes for ways to capitalize on the telehealth megatrend, this one looks like a good choice. On the date of publication, Tom Taulli did not have (either directly or indirectly) any positions in any of the securities mentioned in this article. Tom Taulli (@ttaulli) is the author of various books on investing and technology, including Artificial Intelligence Basics, High-Profit IPO Strategies and All About Short Selling. He is also the author of courses on topics like the Python language and COBOL. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next Potential Winner It doesn’t matter if you have $500 in savings or $5 million. Do this now. #1 Play to Profit from Biden's Presidency The post Is Hims & Hers Health a Good Way To Play the Telehealth Megatrend? appeared first on InvestorPlace.

    View More →
  • Hims & Hers Health, Inc. to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call

    Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, will release fiscal fourth quarter and full year 2020 financial results on Thursday, March 18, 2021 after market close, with a conference call to follow at 5:00 p.m. E.T.

    View More →
  • How COVID-19 has transformed the pharmacy sector

    Yahoo Finance’s Myles Udland, Julie Hyman, and Brian Sozzi discuss M&A outlook in the pharmacy sector with Syed Husain, PJ Solomon Managing Director.

    View More →
  • This telehealth firm started by selling erectile dysfunction pills, now it's an ambitious public company

    Hims & Hers is now a public company after a debut on the New York Stock Exchange on Thursday. Here's what the company's co-founder told Yahoo Finance.

    View More →
  • Hims & Hers CEO on growing business in telehealth space

    Hims & Hers Co-Founder and CEO Andrew Dudum joins Yahoo Finance Live to weigh in on the company's $1.6 billion SPAC deal with Oaktree Capital Management and discuss the future of the telehealth company. 

    View More →